Colin Farrell has been a passionate advocate for

Bioniq founder on why taking a personalized appr

Companies seek to leverage disease risk detectio

The most recent report from The Lancet Commissio

Longevity.

Obesity presents a major global health challenge

Longevity world mourns a pioneer of aging resear

Company targets Phase 2 trial of oral Alzheimer’s drug that inhibits the activity of microglia to combat neuroinflammation. US biotech NeuroTherapia has secured $12.3 million in the first close of a Series B financing round to progress its mission to tackle central nervous system diseases, with an initial focus on Alzheimer’s. While many companies are targeting the removal of toxic proteins like beta amyloid, tau and alpha synuclein, the Cleveland Clinic spinout is addressing neuroinflammation, a factor increasingly recognized as crucial in the progression of CNS diseases. NeuroTherapia’s focus is on developing orally available small-molecule drugs that inhibit the activity of microglia, immune cells in the CNS that contribute to neuroinflammation. By modulating these cells, the company aims to reduce inflammation without disrupting the clearance of toxic proteins, thereby improving neuronal function and survival. Microglia, the central immune cells in the brain, can exist in two states: the neuroprotective M2 phenotype, which helps clear amyloid β, and the neurotoxic M1 phenotype, which contributes to inflammation and synaptic damage. In Alzheimer’s disease and other neurodegenerative conditions, there is an increased prevalence of the M1 state, exacerbating the disease. NeuroTherapia’s lead candidate, NTRX-07, is designed to activate the cannabinoid type 2 (CB2)…

A recent study published in

A recent study published in

In recent years, a staggering 50% decrease in ni

Longevity.

Have you noticed a sudden puffiness or swelling

New study shows that raising levels of fatty aci

On a mission to promote healthier eating habits,

Boosting your lifespan can be as simple as makin

Magnesium is an essential mineral that supports

Longevity.

Imagine struggling to remember simple tasks or f

Summer offers an abundance of delicious foods th

YouthBio Therapeutics has announced what it descr

Transferring regeneration-associated genes from

Company announces PIPE financing of up to $122 m

A recent study published in

Did you know that over

Longevity.

By 2050, over 150 million people could be living

Part of $27 million fund to foster collaboration

New Alzheimer’s drug data highlights increased

A recent study in

Study identifies the nuclear protein Pin1 as piv

Seed round led by SV Health and Two Bear Capital

A new study published in

Recently, there has been a noticeable increase i

Aging impacts everyone, affecting our health and

Longevity.

Rejuvenate Biomed and SAS have announced a collab

Study shows Shingrix vaccine may delay dementia

Cognition Therapeutics reports once-daily drug’s potential to slow Alzheimer’s progression, showing promise with favorable safety profile. Cognition Therapeutics, Inc. recently disclosed findings from their Phase 2 SHINE trial, investigating the efficacy of CT1812, an experimental oral treatment for Alzheimer’s disease. The study, which involved 153 adults with mild-to-moderate Alzheimer’s, assessed the cognitive and functional impacts of daily CT1812 doses over six months, and has reported approximately 40% less cognitive decline in patients administered CT1812 compared with those on a placebo. The SHINE trial, a double-blind, placebo-controlled study, explored two dosages of CT1812 (100mg and 300mg), with the primary objective being the safety and tolerability of the treatment. The drug showed a consistent trend towards cognitive improvement across multiple measures, including an Alzheimer’s Disease Assessment Scale that involved 11 different tasks (ADAS-Cog 11) and a Mini-Mental State Examination based on 11 questions (MMSE). Specifically, by Day 182, participants on placebo experienced a 2.70-point decline on the ADAS-Cog 11 scale, while those on CT1812 showed a lesser decline of 1.66 points – indicating a 39% reduction in cognitive decline in favor of the treatment. Dr Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics, remarked: “A key objective of this trial was to provide…

Arnold Schwarzenegger has significantly boosted

According to registered dietitian and certified

In a recent study published in

Curious about the potential risks and side effec